Updated · Investors | Eli Lilly and Company · May 12
Lilly Says Foundayo, 5-mg Zepbound Preserve Weight Loss in Phase 3 Trials
Updated
Updated · Investors | Eli Lilly and Company · May 12
Lilly Says Foundayo, 5-mg Zepbound Preserve Weight Loss in Phase 3 Trials
5 articles · Updated · Investors | Eli Lilly and Company · May 12
Late-phase data showed Lilly’s oral Foundayo and reduced-dose 5-mg Zepbound helped patients largely maintain prior weight loss after stepping down from higher-dose incretin therapy.
At 52 weeks in ATTAIN-MAINTAIN, patients switching from Wegovy to Foundayo regained just 0.9 kg on average, while those switching from Zepbound to Foundayo regained 5.0 kg.
In SURMOUNT-MAINTAIN, patients staying on maximum-dose Zepbound preserved all prior weight loss at week 112, while those reduced to 5 mg maintained all but 5.6 kg and still beat placebo on the primary endpoint.
The trials enrolled 376 patients in ATTAIN-MAINTAIN and 441 in SURMOUNT-MAINTAIN, with Lilly saying safety profiles matched earlier Phase 3 studies and gastrointestinal side effects remained the most common.
The results bolster Lilly’s push to position obesity as a chronic disease needing long-term treatment, while expanding options from weekly injectable tirzepatide to once-daily oral Foundayo.
Lilly's new obesity drug is here, but what are the long-term health risks that have regulators worried about the future?
With millions set to use new weight-loss drugs, which major industries beyond healthcare are about to be permanently transformed?
This new pill can suppress 'eating for pleasure.' What does this mean for our brains and society's relationship with food?
Foundayo’s FDA Approval: How Eli Lilly’s Oral GLP-1 Pill Could Expand Weight Loss Access for Millions
Overview
Foundayo (orforglipron) is Eli Lilly’s newly FDA-approved oral GLP-1 medication for adults with obesity or overweight and related health problems. Unlike other GLP-1 pills, Foundayo can be taken at any time of day without food or water restrictions, making it highly convenient and designed to improve patient adherence. Clinical trials showed that adults taking the highest dose lost an average of 27 pounds. Foundayo is meant to be used alongside a reduced-calorie diet and increased physical activity, helping people not only lose weight but also maintain their weight loss over time.